Immunoprognostic and Immunotherapeutic Areas
| Prognostic | |
| Immunoscore | |
| Therapeutic | |
| Conventional Therapies | |
| Chemotherapy | |
| Radiation therapy | |
| ITAs - Passive | |
| Cellular Therapy | |
| Adoptive T and NK cells | |
| CAR T cells | |
| ITAs - Active & Specific | |
| Monoclonal Antibodies | |
| Tumor-targeting | |
| Immune-targeting, including checkpoint inhibitors | |
| Vaccines | |
| In situ Vaccines | |
| Cell-based Vaccines | |
| Dendritic cell–based Vaccines | |
| Non–cell-based Vaccines | |
| ITAs - Active & Nonspecific | |
| Cytokines | |
| IDO Inhibitors |
CAR chimeric antigen receptor, ITA immune-targeted agent, IDO indoleamine-2,3-dioxygenase